Analysts forecast that Prestige Consumer Healthcare Inc (NYSE:PBH) will announce sales of $232.23 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Prestige Consumer Healthcare’s earnings, with the lowest sales estimate coming in at $230.80 million and the highest estimate coming in at $234.70 million. Prestige Consumer Healthcare reported sales of $253.98 million during the same quarter last year, which indicates a negative year-over-year growth rate of 8.6%. The business is expected to announce its next quarterly earnings report on Thursday, August 1st.
According to Zacks, analysts expect that Prestige Consumer Healthcare will report full year sales of $954.88 million for the current fiscal year, with estimates ranging from $954.00 million to $955.90 million. For the next year, analysts anticipate that the firm will post sales of $964.10 million, with estimates ranging from $963.50 million to $964.60 million. Zacks’ sales calculations are an average based on a survey of research analysts that follow Prestige Consumer Healthcare.
Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, May 9th. The company reported $0.72 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.70 by $0.02. Prestige Consumer Healthcare had a negative net margin of 3.67% and a positive return on equity of 12.45%. The company had revenue of $241.03 million for the quarter, compared to analyst estimates of $237.22 million. During the same quarter in the prior year, the business posted $0.62 EPS. The firm’s revenue was down 5.8% compared to the same quarter last year.
PBH has been the topic of a number of analyst reports. TheStreet lowered shares of Prestige Consumer Healthcare from a “c” rating to a “d+” rating in a report on Friday, May 10th. Zacks Investment Research lowered shares of Prestige Consumer Healthcare from a “hold” rating to a “sell” rating in a report on Friday, February 1st. Desjardins lowered shares of Prestige Consumer Healthcare to a “hold” rating and set a $88.00 target price on the stock. in a report on Wednesday, February 13th. Royal Bank of Canada reiterated a “buy” rating and issued a $97.00 price objective on shares of Prestige Consumer Healthcare in a research note on Friday, March 15th. Finally, ValuEngine upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “sell” rating in a research note on Monday, April 29th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $54.07.
PBH opened at $30.28 on Wednesday. The company has a current ratio of 2.37, a quick ratio of 1.43 and a debt-to-equity ratio of 1.64. Prestige Consumer Healthcare has a fifty-two week low of $26.25 and a fifty-two week high of $41.76. The stock has a market capitalization of $1.54 billion, a P/E ratio of 10.89, a price-to-earnings-growth ratio of 1.71 and a beta of 0.96.
Large investors have recently bought and sold shares of the business. Premia Global Advisors LLC purchased a new stake in Prestige Consumer Healthcare in the 1st quarter valued at about $26,000. First Hawaiian Bank increased its stake in Prestige Consumer Healthcare by 218.4% in the 4th quarter. First Hawaiian Bank now owns 1,210 shares of the company’s stock valued at $37,000 after buying an additional 830 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in Prestige Consumer Healthcare in the 4th quarter valued at about $37,000. Financial Gravity Wealth Inc. purchased a new stake in Prestige Consumer Healthcare in the 1st quarter valued at about $50,000. Finally, Quadrant Capital Group LLC increased its stake in Prestige Consumer Healthcare by 2,979.3% in the 1st quarter. Quadrant Capital Group LLC now owns 1,786 shares of the company’s stock valued at $53,000 after buying an additional 1,728 shares during the last quarter.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.
See Also: Diversification Important in Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.